Paradigm Biopharmaceuticals Ltd Asset Resilience Ratio
Paradigm Biopharmaceuticals Ltd asset resilience ratio. Paradigm Biopharmaceuticals Ltd (PAR) has an Asset Resilience Ratio of 0.31% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Paradigm Biopharmaceuticals Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Paradigm Biopharmaceuticals Ltd (2016–2025)
Asset resilience ratio of Paradigm Biopharmaceuticals Ltd from 2016 to 2025. This chart shows how Paradigm Biopharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Read debt load of Paradigm Biopharmaceuticals Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Paradigm Biopharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Paradigm Biopharmaceuticals Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$71.83K | 0.31% |
| Total Liquid Assets | AU$71.83K | 0.31% |
Asset Resilience Insights
- Limited Liquidity: Paradigm Biopharmaceuticals Ltd maintains only 0.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Paradigm Biopharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Paradigm Biopharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Paradigm Biopharmaceuticals Ltd Asset Resilience Ratio by Year (2016–2025)
Paradigm Biopharmaceuticals Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Paradigm Biopharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$24.57 Million ≈ $17.39 Million |
-- |
| 2024-06-30 | 0.17% | AU$46.20K ≈ $32.69K |
AU$27.39 Million ≈ $19.38 Million |
+0.10pp |
| 2023-06-30 | 0.07% | AU$46.20K ≈ $32.69K |
AU$67.07 Million ≈ $47.46 Million |
-0.02pp |
| 2022-06-30 | 0.09% | AU$46.20K ≈ $32.69K |
AU$50.69 Million ≈ $35.87 Million |
+0.04pp |
| 2021-06-30 | 0.05% | AU$46.20K ≈ $32.69K |
AU$84.79 Million ≈ $60.00 Million |
-0.61pp |
| 2020-06-30 | 0.66% | AU$746.20K ≈ $527.98K |
AU$112.36 Million ≈ $79.50 Million |
-6.94pp |
| 2019-06-30 | 7.60% | AU$6.50 Million ≈ $4.60 Million |
AU$85.51 Million ≈ $60.50 Million |
-- |
| 2017-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$14.35 Million ≈ $10.15 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$12.35 Million ≈ $8.74 Million |
-- |
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. … Read more